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lowing oxaliplatin based chemotherapy can have a signiﬁcant
impact on post-operative outcome following resection of colorec-
tal liver metastases. To date no relevant experimental models of
oxaliplatin induced SOS have been described. The aim of this pro-
ject was to establish a rodent model which could be utilised to
investigate mechanisms underlying SOS to aid the development
of therapeutic strategies.
Methods: C57Bl/6 mice, maintained on a puriﬁed diet, were trea-
ted with intra-peritoneal FOLFOX (n = 10), or vehicle (n = 10),
weekly for ﬁve weeks and culled one week following ﬁnal treat-
ment. Sections of the liver and spleen were ﬁxed in formalin and
parafﬁn embedded for histological analysis. The role of oxidative
stress on experimental-induced SOS was determined by
dietary supplementation with butylated hydroxyanisole and
N-acetylcysteine.Journal of Hepatology 20
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Abbreviations: AST, aspartate aminotransferase; ALT, alanine aminotransferase;
ALP, alkaline phosphatase; BHA, butylated hydroxyanisole; CRLM, colorectal liver
metastases; CXCL1/2, chemokine (C-X-C motif) ligand 1/2; GAPDH, gyceralde-
hyde 3-phosphate dehydrogenase; H&E, haematoxylin and eosin; HPF, high po-
wered ﬁeld; cH2AX, phosphorylated form of the H2A histone family, member X;
i.p., intraperitoneal; IL-6, interleukin 6; MCP1, monocyte chemotactic protein-1;
NAC, N-acetylcysteine; NRF2, nuclear factor (erythroid-derived 2)-like 2; NQO1,
NAD(P)H dehydrogenase 1; PCNA, proliferating cell nuclear antigen; PAI-1, pla-
sminogen activatior inhibitor 1; PAR 1/2, protease activated receptor 1/2; STAT3,
signal transducer and activator of transcription 3; SOS, sinusoidal obstruction
syndrome; TXN1, thioredoxin 1; VEGF-A/B/C, vascular endothelial growth factor
A/B/C; VEGFR-1/2, vascular endothelial growth factor receptor ½; vWF, von Wi-
llebrand factor.Results: FOLFOX treatment was associated with the development
of sinusoidal dilatation and hepatocyte atrophy on H&E stained
sections of the liver in keeping with SOS. Immunohistochemistry
for p21 demonstrated the presence of replicative senescence
within the sinusoidal endothelium.
FOLFOX induced endothelial damage leads to a pro-thrombotic
state within the liver associated with upregulation of PAI-1
(p <0.001), vWF (p <0.01) and Factor X (p <0.001), which may
contribute to the propagation of liver injury.
Dietary supplementation with the antioxidant BHA prevented
the development of signiﬁcant SOS.
Conclusions:We have developed the ﬁrst reproducible model of
chemotherapy induced SOS that reﬂects the pathogenesis of this
disease in patients. It appears that the use of antioxidants along-
side oxaliplatin based chemotherapy may be of value in prevent-
ing the development of SOS in patients with colorectal liver
metastases.
 2013 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY license.IntroductionA signiﬁcant proportion of patients presenting with colorectal
liver metastases (CRLM) have a pattern of disease that often pre-
vents safe surgical resection. For these patients, the treatment of
choice is systemic chemotherapy in order to downstage disease
in preparation for curative surgery. The most widely utilised reg-
imens for this purpose consist of a thymidylate synthase inhibitor
(either 5-FU/folinic acid or capecitabine) in combination with
either oxaliplatin or irinotecan and, more recently, with the addi-
tion of antibody therapy in the form of bevacizumab or cetux-
imab [1,2]. The success of these regimens in achieving effective
tumour downstaging results in increasing numbers of patients
undergoing liver resection who have received multiple cycles of
prolonged chemotherapy prior to curative surgery.13 vol. 59 j 318–326
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Oxaliplatin based regimens have been associated with the
development of injury to the hepatic parenchyma in the form
of sinusoidal obstruction syndrome (SOS) [3]. SOS is character-
ised by hepatic sinusoidal dilatation, hepatocyte atrophy, peri-
sinusoidal ﬁbrosis, and nodular regenerative hyperplasia [3].
These histological changes appear to be present in up to 40% of
patients treated with oxaliplatin based regimens undergoing liver
resection [4–8]. The presence of SOS is a cause for concern when
undertaking major hepatectomy as it is associated with increased
peri-operative morbidity including post-hepatectomy liver fail-
ure characterised by cholestasis, ascites, and a prolonged pro-
thrombin time [9,10]. More recently, it has been demonstrated
that the presence of SOS is associated with poorer long-term dis-
ease speciﬁc survival following resection of CRLM and, in partic-
ular, an increased risk of intrahepatic recurrence [6,11].
At present very little is known about the pathophysiological
mechanisms which lead to the development of oxaliplatin-
induced SOS and research on these mechanisms is limited by
the lack of an appropriate and reproducible experimental model
of oxaliplatin induced SOS. Whilst the administration of mono-
crotaline to rats leads to similar histological lesions within the
liver, it is not clear if the mechanisms responsible for these
lesions are shared by oxaliplatin.
The aim of the current study was to establish a model of oxa-
liplatin induced SOS relevant to the use of conversion chemother-
apy and to identify molecular mechanisms involved in its
pathogenesis.Materials and methods
The use of animals in this study was reviewed and approved by the local research
ethics committee and the UK home ofﬁce.
In vivo chemotherapy model
To determine the direct toxicity of FOLFOX, 10-week old C57Bl/6 mice were
treated with intraperitoneal (i.p.) oxaliplatin 6 mkg/kg followed 2 h later by
5-FU 50 mg/kg and folinic acid 90 mg/kg (all obtained from Sigma-Aldrich,
Dorset, UK), on a weekly basis for 5 weeks. The drug dosing schedule was
based upon that used in previously published studies and our own preliminary
dose ﬁnding experiments [12–14]. Control animals received vehicle alone.
There were 10 animals per treatment group, although one animal in each
group died during the course of the experiment. Mice were culled one week
after the ﬁnal dose of chemotherapy under isoﬂurane anaesthesia by cardiac
puncture. All animals received standard animal house care, including ad libitum
access to water and a standard puriﬁed diet (D01060501, Research Diets Inc,
New Brunswick, USA).
To determine the effect of antioxidant therapy on the development of FOLFOX
induced SOS, the above experiments were repeated (n = 5 per group) with custom
diets supplemented with either 3% N-acetylcysteine or 0.7% butylated hydroxy-
anisole (Research Diets Inc, New Brunswick, USA). Based upon a typical
dietary intake of 150 g food per kg body weight, this equated to a daily dose of
4.5 g/kg NAC and 1 g/kg BHA per day. The diets were otherwise identical to the
standard puriﬁed diet used above. There was one death in the FOLFOX treated
group receiving a BHA supplemented diet.Microarray analysis
An Illumina mouse microarray (Illumina Inc, San Diego, USA) was performed on
mRNA isolated from the livers of 6 vehicle treated animals and 6 FOLFOX treated
animals (service provided by Genome Centre, Queen Mary University of London,
UK). Analysis was performed using GeneSpring GX software (Agilent Technolo-
gies Inc, Santa Clara, USA).Journal of Hepatology 201Quantitative RT-PCR
Whole liver RNA was isolated using the RNeasy system (Qiagen, West Sussex,
UK) according to the manufacturers’ protocol. cDNA was generated using 1 lg
RNA, MMLV-RT, and a random hexamer primer (Promega, Southampton, UK).
SYBR-green reagents (Sigma-Aldrich, Dorset, UK) were utilised for qRT-PCR with
fold change in gene expression calculated using the DDCT method. GAPDH was
used as the internal control. Primer sequences are listed in Supplementary
Table 1.
Western blot
Protein was extracted from whole liver tissue in RIPA buffer and quantiﬁed using
the Bradford assay (Bio Rad, UK). Fifty lg of protein was loaded onto acrylamide
gels and separated by SDS-page prior to transfer to nitrocellulose. Proteins were
detected with antibodies as listed in Supplementary Table 2 and visualised by
chemiluminescence. GAPDH was used as the loading control.
Total glutathione content
The automated glutathione recycling method described by Anderson was
used to assess the total glutathione content in liver samples [15], using a
96-well plate reader (Powerwave X340, Bio-tech instruments Inc, Vermont,
USA). The protein content of samples was determined using the method of Lowry
et al. [16].
ELISA
Serum was separated from clotted whole blood samples obtained after cardiac
puncture and diluted 1:3 in PBS/1% BSA. CXCL1 and VEGF were measured in
the serum using a commercial ELISA development kit, according to the manufac-
turers’ instructions (R&D Systems, Minneapolis, USA).
Histological assessment
Five lm thick slices of tissue were cut from formalin ﬁxed and parafﬁn embed-
ded tissue and stained with haematoxylin and eosin (H&E). The presence of
sinusoidal injury was assessed by two specialist liver pathologists blinded to
the treatment group (ADB and FO). In addition, the degree of sinusoidal dilatation
was graded according to the method of Rubbia-Brandt. The disruption and loss of
the endothelial layer within sinusoids were graded as either absent or present
[17].
Immunohistochemistry
Sections were deparafﬁnised, rehydrated and endogenous peroxidase activity
blocked. Non-speciﬁc antibody binding was prevented by blocking of avidin
and biotin (Vector Laboratories, Burlingame, USA) followed by incubation for
30 min in 20% swine serum. Sections were incubated with the primary antibody
overnight at 4 C. The next morning, sections were incubated with a biotin con-
jugated secondary antibody for 2 h followed by a 1-h incubation with streptavi-
din biotin-peroxidase complex (Vector Laboratories, Burlingame, USA). Staining
was visualised with 3,30-diaminobenzidine tetrahydrochloride (Vecto Laborato-
ries, Burlingame, USA) and sections counterstained with haematoxylin. The
details of the antibodies used along with methods of antigen retrieval are listed
in Supplementary Table 3. Staining was quantiﬁed using Leica Qwin software
(Leica Microsystem (UK) Ltd, Buckinghamshire, UK) using 20magniﬁcation with
25 images per slide being assessed.
Splenic megakaryocytes were assessed in 10 magniﬁed sections with
results representing the mean count for 15 images per section.
Statistical analysis
Continuous variables were assessed with Mann-Whitney U-Test with p <0.05
considered statistically signiﬁcant. Categorical variables were compared with
Fisher’s exact test. Analysis was performed in GraphPad Prism (GraphPad Soft-
ware, La Jolla, USA). On ﬁgures, p values are abbreviated as ⁄60.05, ⁄⁄60.01,
⁄⁄⁄60.001.3 vol. 59 j 318–326 319
Fig. 1. Endothelial senescence in FOLFOX induced SOS. (A) Mice maintained on
a puriﬁed diet and treated with intraperitoneal FOLFOX for 5 weeks (n = 9 per
group) demonstrate histological changes of SOS on H&E stained sections of the
liver. (B) To identify potential biological processes implicated in the pathogenesis
of FOLFOX induced SOS, a microarray was performed using mRNA isolated from 6
animals in each group, a heat map of which is shown. (B) Cellular senescence was
identiﬁed as a key mechanism in FOLFOX induced SOS, with upregulation of
p21Cip1 at both a transcript level (C; n = 8 animals per group) and protein level (D;
representative blot of n = 6 per group). (E) Immunohistochemistry revealed that
p21Cip1 staining is limited to endothelial cells at the site of sinusoidal injury
(yellow arrows). (F) Densitometry (n = 9 animals per group) conﬁrmed an
increased intensity of p21Cip1 staining. (G) It is likely that endothelial senescence
is driven by p53 with Western blot of whole liver protein extracts revealing
increased phosphorylation of this transcription factor at serine 15 (representative
blot of n = 6 per group). ⁄p <0.05; ⁄⁄⁄p <0.001. (This ﬁgure appears in colour on the
web.)
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Research ArticleResults
Development of a reproducible in vivo experimental model
To assess the effect of FOLFOX on liver parenchyma, C57Bl/6 mice
were treated with i.p. FOLFOX for 5 weeks and culled one week
after the ﬁnal dose. Blinded review of H&E stained sections of
the liver demonstrated evidence of sinusoidal dilatation and320 Journal of Hepatology 201associated hepatocyte atrophy (Fig. 1A) in all 9 FOLFOX treated
animals, whereas they were absent in all animals in the control
arm (p <0.0001). These histological changes were present homog-
enously throughout the liver with sinusoidal dilatation being of
grade 1 in all animals in the FOLFOX group, whereas there was
no sinusoidal dilatation detected in any animal in the control
group.
Similarly, sinusoidal endothelial disruption was absent within
all animals in the control arm, but was present in every FOLFOX
treated animal (p <0.0001; Supplementary Table 4).
The presence of SOS was associated with evidence of hepato-
cellular injury as demonstrated by elevated AST and ALT in FOL-
FOX treated animals (Supplementary Fig. 1A). It is noteworthy
that when these experiments were performed utilising a stan-
dard chow diet, no such histological changes were demonstrated
(Supplementary Fig. 1B). This model has been repeated on 3 sep-
arate occasions and the histological changes found to be entirely
reproducible with minimal variation in the severity of injury.
In order to identify the key molecular mechanisms underpin-
ning the development of SOS following FOLFOX administration, a
microarray was performed on whole liver mRNA from 6 animals
in each group. This demonstrated upregulation greater than 1.5
fold of 338 transcripts and downregulation greater than 1.5 fold
of 267 transcripts, in FOLFOX treated animals (Fig. 1B; Supple-
mentary Table 5). These results were validated by performing
qRT-PCR for the 7 most highly up and downregulated transcripts
(Supplementary Table 6). Pathway analysis using GeneSpring GX
software revealed that biological pathways related to cell cycle
regulation, oxidative stress, angiogenesis, matrix remodelling,
and the coagulation cascade may all be implicated in the patho-
genesis of FOLFOX induced SOS and these were therefore
explored in greater detail. The key genes identiﬁed from the
microarray for each of these pathways are summarised in Supple-
mentary Table 7.
Cell cycle regulation
Microarray analysis of liver tissue revealed one of the most highly
upregulated genes in FOLFOX treated animals to be the cyclin
dependent kinase inhibitor p21Cip1. This ﬁnding was conﬁrmed
both at the mRNA level by qRT-PCR (21 fold; p <0.001; Fig. 1C)
and protein level by Western blot (Fig. 1D). Immunohistochemis-
try demonstrated a 1.7 fold increase in p21Cip1 expression
(p <0.05), which was localised predominantly to endothelial cells
in areas of sinusoidal injury (Fig. 1E and F).3 vol. 59 j 318–326
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Fig. 2. Cytokine response to sinusoidal injury. (A) Microarray suggested upregulation of the senescence associated chemokine CXCL1 in the liver of FOLFOX treated mice,
which was conﬁrmed by qRT-PCR (n = 8 animals per group). (B) Furthermore, CXCL1 was demonstrated to be elevated within the serum of mice with FOLFOX induced SOS
(n = 9 animals per group). (C) qRT-PCR demonstrated upregulation of other senescence associated inﬂammatory mediators including CXCL2, MCP-1, and IL-6 (n = 8 animals
per group). (D) IL-6 is more typically described as a pro-proliferative cytokine implicated in liver regeneration where it signals through activation of the transcription factor
STAT3. Microarray and subsequent qRT-PCR demonstrated increased expression of this transcription factor in FOLFOX treated animals (n = 8 animals per group). Western
blot demonstrated activation of this transcription factor by phosphorylation (E; representative blot of n = 6 per group), which immunohistochemistry revealed to be
occurring predominantly in hepatocytes around portal tracts (F). Densitometry conﬁrmed the increase in phosphorylated STAT3 seen on Western blot (F; n = 9 animals per
group). ⁄p <0.05; ⁄⁄p <0.01; ⁄⁄⁄p <0.001. (This ﬁgure appears in colour on the web.)
JOURNAL OF HEPATOLOGYIncreased p21Cip1 expression is classically considered to be a
marker of replicative senescence, a process which is character-
ised by cell cycle arrest in G1 phase [18]. Oxaliplatin induced
SOS has previously been associated with upregulation of the
tissue plasminogen activation inhibitor PAI-1 (SERPINE1), a
ﬁnding which is consistent with replicative senescence in this
condition and which has been conﬁrmed in the current model
with a 2800 fold increase at the mRNA level in the liver of
FOLFOX treated mice (p <0.001; Supplementary Fig. 2A)
[19,20]. Immunohistochemistry for the senescence marker
cH2AX demonstrated a signiﬁcant increase in the number of
positive cells within the liver of FOLFOX treated mice, the pat-
tern of staining of which was similar to that of p21Cip1
(p <0.001; Supplementary Fig. 2B and C).
The expression of both p21Cip1 and PAI-1 is regulated by the
transcription factor p53 [21]. In response to cellular injury, e.g.,
DNA damage or oxidative stress, p53 undergoes phosphorylation
and becomes transcriptionally active [22]. In mice with FOLFOX
induced SOS, increased phosphorylation of p53 at serine 15 was
detected in whole liver protein extracts (Fig. 1G), suggesting that
this may be a driver of senescence in this context.
Cellular senescence is associated with increased expression of
a variety of chemokines/cytokines. Microarray analysis revealed
that one such chemokine, CXCL1, was upregulated 3.3 fold in
the liver of FOLFOX treated animals as compared to controls, a
ﬁnding conﬁrmed by qRT-PCR (Fig. 2A; p <0.001). CXCL1 is the
murine homologue of the human cytokine IL-8, increased levels
of which have been reported in the serum of patients with SOS
following bone marrow transplantation [23]. In keeping with this,Journal of Hepatology 201there was a dramatic increase in the serum CXCL1 concentration
of FOLFOX treated mice (Fig. 2B; p <0.01).
qRT-PCR was able to conﬁrm upregulation of other key
inﬂammatory mediators implicated in the senescence response
(Fig. 2C) including CXCL2 (4.2 fold; p <0.001), MCP-1 (12.5 fold;
p <0.001) and IL-6 (2.0 fold; p <0.05) in the liver of FOLFOX trea-
ted mice. Whilst IL-6 has been implicated in the maintenance of
senescence [24], it is more widely considered as a pro-prolifera-
tive cytokine, for example in liver regeneration, where it signals
through JAK1/STAT3 [25]. Micro-array, and subsequent qRT-
PCR, demonstrated that hepatic expression of STAT3 was signiﬁ-
cantly increased in the liver of FOLFOX treated mice (Fig. 2D;
p <0.001), suggesting a potential role for this pathway in the
pathogenesis of SOS and, therefore, this was explored in more
detail.
In response to IL-6, STAT3 is activated by phosphorylation,
whereby it acts as a transcriptional regulator of a wide variety
of target genes which, in the liver, are involved in a variety of pro-
cesses, including hepatocyte regeneration [26]. Western blot
demonstrated increased phosphorylation of STAT3 within the
liver of FOLFOX treated mice (Fig. 2E), which immunohistochem-
istry demonstrated to be located predominantly within the
nucleus of hepatocytes around portal tracts (Fig. 2F). It is of note
that this is the region in which regenerative hyperplasia is seen in
patients with advanced SOS and, as such, it appears likely that
this is driven by IL-6 mediated activation of STAT3. In support
of this hypothesis, there was a 1.8-fold increase in density of
PCNA staining in the liver of animals with SOS (p <0.05; Supple-
mentary Fig. 3).3 vol. 59 j 318–326 321
Fig. 3. Oxidative stress in FOLFOX induced SOS. (A) To assess the role of
oxidative stress in the development of SOS, the experiment was repeated, but this
time supplementing the diet with 0.7% BHA with the puriﬁed diet serving as a
control. Supplementation with 0.7% BHA prevented the development of sinusoi-
dal injury. (B) In keeping with this, there was decreased expression of p21Cip1 and
PAI-1 transcript (n = 5 per group, n = 4 in the FOLFOX and BHA group) in the livers
of these animals. (C) The reduction in p21 expression was conﬁrmed at a protein
level byWestern blot (representative blot of n = 2 per group). (D) FOLFOX induced
SOS is associated with diminished expression of the antioxidant transcription
factor NRF2 which is prevented when BHA is administered (representative blot of
n = 2 per group). (E) BHA supplementation is associated with increased expres-
sion of the NRF2-regulated antioxidant genes TXN1 and NQO1 (n = 5 per group,
n = 4 in the FOLFOX and BHA group). ⁄p <0.05; ⁄⁄p <0.01; n.s, not signiﬁcant. (This
ﬁgure appears in colour on the web.)
Vehicle FOLFOX
C
on
tro
l d
ie
t
0.
7%
 B
H
A
E F
A
B
C
D
10x
Vehicle
FOLFOX
30
20
10
0
R
LT
D
p21Cip1
*
Control
diet
0.7%
BHA
Vehicle
FOLFOX
3
2
1
0
R
LT
D
TXN1
**
n.s
**
Control
diet
0.7%
BHA
Vehicle
FOLFOX
20
15
10
5
0
R
LT
D
NQO1
**
*
Control
diet
0.7%
BHA
8000
6000
4000
2000
0
R
LT
D
PAI-1
*
Control
diet
0.7%
BHA
kDa
70
34 GAPDH
NRF2
Ve
hi
cl
e
FO
LF
O
X
Ve
hi
cl
e
FO
LF
O
X
0.7% BHA dietControl diet
Ve
hi
cl
e
FO
LF
O
X
Ve
hi
cl
e
FO
LF
O
X
0.7% BHA dietControl diet
kDa
21
34 GAPDH
p21Cip1
Research ArticleOxidative stress induced sinusoidal injury
One of the mechanisms for cellular excretion of oxaliplatin is
through conjugation of the active drug to glutathione, which
can then lead to intracellular depletion of this antioxidant [27].
It is known that endothelial depletion of glutathione is a key pro-
cess in monocrotaline induced SOS [28]. Compared with animals322 Journal of Hepatology 201treated with vehicle control alone, total liver glutathione in mice
with FOLFOX induced SOS was signiﬁcantly reduced (95.4 vs.
76.9 lmoles/g protein; p <0.05; Supplementary Fig. 4A). In sup-
port of a role for oxidative stress in the pathogenesis of oxalipla-
tin induced SOS, microarray revealed upregulation of a variety of
genes implicated in the response to oxidative stress, including
metallothionein 1 (Mt1), heme oxygenase 1 (HO1), and superox-
ide dismutase 3 (SOD3), the expression of all of which was con-
ﬁrmed by qRT-PCR (Supplementary Fig. 4B) and, in the case of
SOD3, by Western blot (Supplementary Fig. 4C).
To determine if antioxidant therapy could be of value in pre-
venting the development of oxaliplatin induced SOS, the current
experiment was repeated utilising dietary supplementation with
either 3% N-acetylcysteine (NAC) or 0.7% butylated hydroxyani-
sole (BHA), both of which are effective anti-oxidants in mice
[29,30]. The standard puriﬁed diet was used as a control. Dietary
supplementation was commenced 1 week prior to starting FOL-
FOX and continued until animals were culled one week after
the ﬁnal dose. Review of H&E stained sections showed that NAC
treatment had no effect on SOS development whereas BHA
reduced the severity of sinusoidal injury (Fig. 3A; Supplementary
Fig. 4D). Speciﬁcally, the incidence of endothelial disruption was
reduced to only 25% in FOLFOX treated animals receiving a BHA
supplemented diet (p <0.05; Supplementary Table 8).
In keeping with the histological ﬁndings, there was a statisti-
cally signiﬁcant reduction in the senescence markers p21Cip1 and
PAI-1 at the transcript level, in the liver of FOLFOX treated mice
receiving the BHA supplemented diet as compared with control
diet (Fig. 3B). The reduction in p21Cip1 expression in mice receiv-
ing BHA supplementation was conﬁrmed by Western blot
(Fig. 3C).
BHA exerts its effect through increased transcriptional activity
of the antioxidant transcription factor NRF2 [30]. Relative to con-
trol animals, hepatic NRF2 protein expression levels were
reduced in mice treated with FOLFOX (Fig. 3D). This diminution
of NRF2 was prevented in FOLFOX treated animals receiving the
BHA supplemented diet (Fig. 3D). To determine the functional
effects of BHA on transcription of genes downstream of NRF2,
qRT-PCR was performed for the classically NRF2 regulated anti-
oxidant genes TXN1 (thioredoxin 1) and NQO1 (NAD(P)H dehy-
drogenase 1). In animals with FOLFOX induced SOS, we
observed a 3-fold reduction in TXN1 expression (p <0.01;
Fig. 2E) which was prevented in animals receiving BHA supple-
mentation. SOS was not associated with a reduction in NQO1
expression, however, BHA supplementation was associated with
a 19-fold increase in NQO1 expression (p <0.01; Fig. 2F) suggest-
ing added protection from oxidative stress in these animals.3 vol. 59 j 318–326
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Fig. 4. Angiogenesis in FOLFOX induced SOS. (A) FOLFOX induced SOS is associated with upregulation of the angiogenic factors VEGF-A and VEGF-C, but not VEGF-B, at the
transcript level within the liver (n = 8 per group). (B) This is reﬂected in an increase in serum VEGF-A levels in mice with FOLFOX induced SOS (n = 9 per group). (C) In
addition there is increased expression of the VEGF receptors VEGFR-1 and VEGFR-2 within the liver of FOLFOX treated animals (n = 8 per group). Previous reports have
suggested that, in the context of SOS, VEGF mediated signalling results in phosphorylation of JNK leading to increased expression of MMP-9 [31]. In support of a role for this
mechanism in FOLFOX induced SOS, (D) Western blot revealed increased phosphorylation of JNK within the liver of FOLFOX treated animals (representative blot of n = 6 per
group) with (E) an associated increase in MMP-9 transcript (n = 8 per group). (F) BHA treatment protects against the FOLFOX induced increase in both VEGF-A and VEGFR-1
transcript expression (n = 5 per group, n = 4 in the FOLFOX and BHA group). ⁄⁄p <0.01; ⁄⁄⁄p <0.001.
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There is a growing body of evidence from several cohort studies
to suggest that the addition of bevacizumab, a monoclonal anti-
body directed against VEGF-A, to oxaliplatin based chemotherapy
can reduce the incidence of SOS by approximately a third in
patients [7]. In support of these observations, we were able to
demonstrate increased transcript expression of the angiogenesis
related genes VEGF-A (2.1 fold; p <0.001) and VEGF-C (1.8 fold;
p <0.001), but not VEGF-B, in mice with FOLFOX induced SOS
(Fig. 4A). This was reﬂected in an increased serum concentration
of VEGF-A in FOLFOX treated mice (p <0.001; Fig. 4B).
The microarray study demonstrated upregulation of members
of the VEGF family with subsequent qRT-PCR, demonstrating a 2
fold increase in expression of both VEGFR-1 and VEGFR-2
(Fig. 4C). It has recently been reported in the monocrotaline
model that signalling through the VEGF system leads to phos-
phorylation of c-Jun N-terminal kinase (JNK) and subsequent
upregulation of MMP9 expression, which plays a pivotal role in
the pathogenesis of SOS [31]. This mechanism also appears to
be of relevance in oxaliplatin induced SOS, with Western blot
demonstrating increased JNK phosphorylation and MMP9 tran-
script expression within the liver of FOLFOX treated animals
(Fig. 4D and E). It is also noteworthy that dietary supplementa-
tion with 0.7% BHA prevented the FOLFOX induced increase in
VEGF-A and VEGFR-1 transcripts, suggesting that the level of
expression correlates with the severity of liver injury (Fig. 4F).
The effects of FOLFOX on the VEGF system appeared to be spe-
ciﬁc with no evidence of increased expression of other key angio-Journal of Hepatology 201genic factors (i.e., angiopoietin 1 and 2) or their receptors (i.e., TIE
2) being detected within the liver of FOLFOX treated animals
(data not shown).
SOS is associated with a pro-thrombotic environment within the
injured hepatic sinusoid
Analysis of the microarray suggested activation of the coagula-
tion cascade in the pathogenesis of oxaliplatin induced SOS, with
upregulation of von Willebrand factor (vWF), a key component in
platelet adhesion, in the liver of FOLFOX treated mice, which was
conﬁrmed by qRT-PCR (p <0.01; Supplementary Fig. 5A). Given
the observation that splenomegaly is a feature of patients treated
with oxaliplatin induced SOS [32], we reviewed H&E stained sec-
tions of the spleen of FOLFOX treated mice and observed the pres-
ence of large clusters of megakaryocytes within these animals,
which were not present within control animals (p <0.001; Sup-
plementary Fig. 5B and C). This suggests that an increasing num-
ber of platelets may be released directly into the portal
circulation of FOLFOX treated animals which, in the context of
the elevated liver vWF expression, may be of importance in the
pathogenesis of SOS.
Further support for this hypothesis is that a pro-thrombotic
factor is of importance in the pathogenesis of oxaliplatin induced
SOS, such that Factor X transcript expression is upregulated
within the liver of FOLFOX treated mice (p <0.001; Supplemen-
tary Fig. 5D). Additionally increased expression of tissue factor,
an essential component in the activation of Factor X, was
observed by immunohistochemistry in the region of injured3 vol. 59 j 318–326 323
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hepatic sinusoids (Supplementary Fig. 5E). In keeping with a role
for this process in driving the matrix remodelling associated with
SOS, FOLFOX treatment was also associated with increased hepa-
tic expression of the Factor Xa receptors PAR1 (3.9 fold; p <0.01)
and PAR2 (2.1 fold; p <0.05) (Supplementary Fig. 5F).
The effects of FOLFOX treatment on the coagulation system
appear to be independent of oxidative stress, with 0.7% BHA
treatment having no effect on the expression of either Factor X
or vWF (data not shown).
Liver ﬁbrosis
Chronic liver injury typically results in thedevelopmentof liverﬁbro-
sis which is characterised by extracellular deposition of collagen
ﬁbres within the liver. In support of such a process, upregulation of
3 collagen genes in FOLFOX treated animals was observed onmicro-
array (Supplementary Table 7). Liver ﬁbrosis is associatedwith trans-
formation of quiescent hepatic stellate cells into activated
myoﬁbroblasts, whereby they express high levels of alpha smooth
muscle actin (aSMA) and pro-collagen I, a process which is driven
by the socalledmaster regulatorof liverﬁbrosisTGFb [33]. In the liver
of FOLFOX treated animals, therewas upregulation of both TGFb (3.5
fold; p <0.01) and procollagen I (6 fold; p <0.001). There was also a
modest increase inaSMAexpression, but thisdifferencedidnot reach
statistical signiﬁcance (1.9 fold; p = 0.195; Supplementary Fig. 6A).
Reviewof Sirius Red stained sections of the liver suggested very early
collagen deposition within the injured hepatic sinusoids of FOLFOX
treated animals (Supplementary Fig. 6B) although established ﬁbro-
sis was not present, suggesting that this is a late event in FOLFOX
induced liver injury.Discussion
This paper presents the ﬁrst report of a reproducible experi-
mental chronic model of oxaliplatin induced SOS, which can
be used to explore in detail the pathogenesis of this condition.
Prior to this report, the only model which was thought to gen-
erate similar histological features of SOS was monocrotaline
administration to rats [34]. The monocrotaline model has sev-
eral limitations, which the authors believe make it unsuitable
for the study of oxaliplatin induced SOS, in relation to patients
receiving conversion therapy for colorectal liver metastasis.
The most obvious is that the stimulus driving the histological
changes is different and as such there is a signiﬁcant risk that
the molecular mechanisms underpinning the histological
changes will be distinctly different from those driving the
pathology in oxaliplatin treated patients. Moreover, the develop-
ment of SOS in response to monocrotaline is an acute event
occurring within hours whereas oxaliplatin induced SOS occurs
as a consequence of chronic drug exposure. Similarly, monocro-
taline induced SOS is associated with a lobular inﬂammatory
inﬁltrate, consisting of mainly neutrophils, whereas this is not
described in patients treated with oxaliplatin. A further difﬁ-
culty with the monocrotaline model is that its administration
to rats results in the development of pulmonary hypertension
which is not a feature in patients treated with oxaliplatin
[35,36]. The presence of such pathology is likely to have a sig-
niﬁcant physiological impact, thereby limiting the utility of this
model in studying either the functional consequences of SOS or
in the development of preventative therapeutic strategies.324 Journal of Hepatology 201An unexpected observation in the current study was that
feeding a chow diet seems to protect against the development
of SOS in response to FOLFOX. Chow diets are manufactured pre-
dominantly from plant materials and thereby differ considerably
from puriﬁed diets, such as those used in this study, which are
manufactured with reﬁned (and deﬁned) ingredients. A conse-
quence of this is that chow diets may contain high concentrations
of phytoestrogens (and other bioactive ingredients) which have
been shown to have protective effects on the development of
liver ﬁbrosis and hepatic steatosis [37,38]. Determining how a
chow diet protects against SOS was beyond the scope of this
study but further investigation of this apparent protection may
help identify a potential therapeutic approach for use in patients
receiving oxaliplatin based chemotherapy regimens.
PAI-1 expression was signiﬁcantly elevated (x 2800 fold) in
mice with FOLFOX induced SOS, suggesting it plays a central role
in the pathogenesis of this condition. Indeed, PAI-1 has been
implicated in all of the key pathological processes identiﬁed in
this model thus far, i.e., clotting dysfunction, matrix remodelling
and replicative senescence [39]. PAI-1 is transcriptionally regu-
lated by p53, particularly in the context of senescence, which in
this model occurs in response to chemotherapy induced DNA
damage (within the sinusoidal endothelium). PAI-1 is not a pas-
sive marker of senescence, but rather is essential for its induction
and maintenance by downregulating signalling through the mito-
genic PI3K-PKB pathway utilised by many growth factors [21].
The most signiﬁcant ﬁnding in the current study is that oxida-
tive stress appears to play a major role in the pathogenesis of FOL-
FOX induced SOS,which can be prevented by the administration of
the antioxidant BHA. The type of antioxidant used may be critical,
sincewe have demonstrated that the thiol donorNAC is ineffective
in the prevention of SOS. This is in contrast to the work by Wang
et al. in the monocrotaline model where intraportal infusion of
both glutathione and NAC was effective [28]. An explanation for
this apparent disagreement may be that the route of administra-
tion chosen in our study (provision in the diet) did not allow sufﬁ-
cient concentrations of NAC to reach the portal circulation.
However, this seems a little unlikely since NAC is absorbed readily,
and rapidly transported to the liver via the portal vein [40]. The
enteral route for NAC administration is more clinically relevant
since the addition of daily parenteral therapy alongside systemic
chemotherapy would be deemed unacceptable by patients.
In contrast, antioxidants whose effect is mediated through the
activation of NRF2 appear to have the potential to prevent the
development of SOS. Curcumin is one example of a clinically rel-
evant substance which works through this pathway [41]. This is
of particular interest since curcumin is currently the subject of
much investigation as an adjunct to conventional chemotherapy
because of its cytotoxic properties [42]. It may therefore be pos-
sible, through the targeting of NRF2, to not only reduce the inci-
dence and severity of SOS, but also to increase the efﬁcacy of
conventional chemotherapy and this is worthy of further
investigation.
We have identiﬁed the generation of a pro-thrombotic envi-
ronment within the hepatic sinusoid as potentially important in
the pathogenesis of SOS. Support for this hypothesis comes from
the observation that patients taking regular aspirin appear to be
at lower risk of developing oxaliplatin induced SOS [43]. Further-
more the ﬁbrinolytic deﬁbrotide has demonstrated modest suc-
cess in treating patients with SOS who received myeloablative
chemotherapy prior to bone marrow transplants [44]. A possible3 vol. 59 j 318–326
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explanation for how a prothrombotic environment contributes to
the development of SOS is that it results in the generation ofmicro-
thrombiwithin the hepatic sinusoids,which subsequently become
occluded, causing portal hypertension. An alternative explanation
could be provided by the signiﬁcant crosstalk that exists between
the clotting cascade and the process of matrix remodelling. Factor
Xa, acting through protease activated receptor 1 (PAR-1), can con-
vert TGFb from its latent to active forms [45]. It has been shown
that PAR-1 knockout mice have less ﬁbrosis than wild types after
treatment with carbon tetrachloride [46], and administration of a
PAR-1 antagonist to mice subject to bile duct ligation leads to a
reduction in hepatic ﬁbrosis [47]. At present, the role of PAR-1 sig-
nalling in SOS development is uncertain, but it is conceivable that
its antagonism, or indeed of Factor Xa, may lead to a reduction in
perisinusoidal ﬁbrosis seen in the severest forms of the disease
and this is worthy of further exploration.
It should be noted that in the present study we have only pro-
vided hypotheses generating gene and protein expression data,
which suggest a potential role for the coagulation system in the
pathogenesis of SOS. To deﬁnitively establish a role for the coag-
ulation cascade in this process, a more detailed analysis would be
required, which should include focused activity assays with sub-
sequent in vivo therapeutic intervention experiments, to deter-
mine the potential utility of anticoagulant strategies in
preventing the development of SOS.
Two recent publications have examined gene expression
changes within the liver of a cohort of patients with oxaliplatin
induced SOS using microarray technology. These studies identi-
ﬁed key processes involved in the pathogenesis of human SOS,
which have also been implicated in the current model including
activation of the IL-6/STAT3 pathway, activation of the coagula-
tion system (in particular overexpression of PAI-1 and vWF), as
well as overexpression of genes involved in cellular hypoxia
and oxidative stress. Whilst both of these studies demonstrated
upregulation of angiogenesis related genes, particularly VEGF-C
and VEGF-D, we have in this experimental model demonstrated
for the ﬁrst time a direct association between oxaliplatin induced
SOS and increased expression of VEGF-A [19,48]. This ﬁnding
adds further weight to the clinical observation that bevacizumab
may be effective in reducing the incidence and severity of SOS
following treatment with oxaliplatin based chemotherapy [7].
In conclusion, this paper describes a novel, reproducible
model of SOS following treatment with oxaliplatin based chemo-
therapy, which we have used to elucidate some of the key path-
ophysiological processes which underpin this condition. By
targeting speciﬁc pathways, it may be possible to reduce the inci-
dence and severity of SOS without having a detrimental effect on
the efﬁcacy of systemic chemotherapy and thereby reduce the
surgical morbidity after potentially curative liver resection.Financial support
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